티보자닙 처리에 의한 OSCC 세포의 항암활성 효과
The Anticancer Activity Effects of Tivozanib in OSCC Cell Lines
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
티보자닙(Tivozanib)은 주로 신세포암 치료에 사용되는 티로신 키나아제 억제제(Tyrosine Kinase Inhibitors, TKIs)로 혈관 내피 성장인자 수용체(Vascular Endothelial Growth Factor Receptors, VEGFRs) 를 표적으로 하여 종양으로 가는 혈액 공급을 억제함으로써 암세포의 성장과 전이를 억제하는 것으로 알려져 있다. 신장에 발생하는 종양과 티보자닙의 연관성에 관한 논문은 비교적 많은 보고가 된 바 있으나 구강암에서의 티보자닙의 항암활성 효과는 아직 밝혀진 바가 거의 없다. 따라서 본 연구에서는 구강편평상피세포암종 세포주인 Ca9-22와 CAL-27세포에 티보자닙을 처리하여 암 발생 과정과 밀접한 관련이 있는 세포자멸사와 자가포식작용 사이의 연관성을 밝힘으로써 구강암의 치료제로서의 효능을 입증하기 위하여 시행되었다. 실험 결과 티보자닙은 Ca9-22와 CAL-27 세포에서 내인성 경로를 통한 세포자멸사와 초기 자가포식 작용 연관 단백질의 발현을 유의미하게 조절함으로써 효과적으로 항암 활성 효과를 나타내었음을 입증하였다.
Abstract
Tivozanib is a tyrosine kinase inhibitor (TKI) used in the treatment of renal cell carcinoma. It targets vascular endothelial growth factor receptors (VEGFRs) within the tumor, inhibiting the blood supply to the tumor, which in turn, suppresses the growth and spread of cancer cells. While there have been numerous reports highlighting the association between diseases in the kidneys and Tivozanib, its pharmacological effects on oral cancer remain largely unexplored. Therefore, this study aimed to investigate the relationship between Tivozanib and the mechanisms related to cancer cell death (apoptosis) and autophagy in Ca9-22 and CAL-27 oral squamous cell carcinoma cell lines. The objective was to demonstrate an increased efficacy in treating oral cancer cells. The results showed that Tivozanib effectively exhibited its anti-cancer activity by regulating the expression of proteins associated with intrinsic cell apoptotic pathways and early autophagy in Ca9-22 and CAL-27 cells.
참고문헌 (24)
- Crispian Scully, "Oral squamous cell carcinoma overview", Oral Oncology, 45(4-5), pp.301~308 (2009), Elsevier BV[DOI]
- Collins, S., "Overview of management for oral cavity squamous cell carcinoma(SCC)1988", Ill Dent J, 57(5), pp.340~341 (1988)
- Yu Oikawa, "Management of retropharyngeal lymph node metastasis in oral cancer", Oral Oncology, 99, pp.104471~ (2019), Elsevier BV[DOI]
- Takumi Hasegawa, "The prospective evaluation and risk factors of dysphagia after surgery in patients with oral cancer", Journal of Otolaryngology - Head & Neck Surgery, 50(1) (2021), SAGE Publications[DOI]
- Mark S. Chambers, "Stomatitis associated with mammalian target of rapamycin inhibition", The Journal of the American Dental Association, 149(4), pp.291~298 (2018), Elsevier BV[DOI]
- Benedito A. Carneiro, "Targeting apoptosis in cancer therapy", Nature Reviews Clinical Oncology, 17(7), pp.395~417 (2020), Springer Science and Business Media LLC[DOI]
- Steven He, "Proliferation and Apoptosis Pathways and Factors in Oral Squamous Cell Carcinoma", International Journal of Molecular Sciences, 23(3), pp.1562~ (2022), MDPI AG[DOI]
- Tammy M. Holm, "Targeting Autophagy in Thyroid Cancer: EMT, Apoptosis, and Cancer Stem Cells", Frontiers in Cell and Developmental Biology, 10 (2022), Frontiers Media SA[DOI]
- Juan Zhang, "Autophagy Regulators in Cancer", International Journal of Molecular Sciences, 24(13), pp.10944~ (2023), MDPI AG[DOI]
- Laura Caquelin, "Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature", BMC Cancer, 22(1) (2022), Springer Science and Business Media LLC[DOI]
- Saes, L., "Tivozanib: A new treatment option for renal cell carcinoma", Drugs of Today, 53(11), pp.609~ (2017), Portico[DOI]
- Yi-Tzu Chen, "Erianin Induces Apoptosis and Autophagy in Oral Squamous Cell Carcinoma Cells", The American Journal of Chinese Medicine, 48(01), pp.183~200 (2020), World Scientific Pub Co Pte Ltd[DOI]
- Tompkins, K. D., "Regulation of Apoptosis by Autophagy to Enhance Cancer Therapy", Yale J Biol Med, 92(4), pp.707~718 (2019)
- João Massano, "Oral squamous cell carcinoma: Review of prognostic and predictive factors", Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 102(1), pp.67~76 (2006), Elsevier BV[DOI]
- Anastasios K Markopoulos, "Current Aspects on Oral Squamous Cell Carcinoma", The Open Dentistry Journal, 6(1), pp.126~130 (2012), Bentham Science Publishers Ltd.[DOI]
- Katrien Vermeulen, "Apoptosis: mechanisms and relevance in cancer", Annals of Hematology, 84(10), pp.627~639 (2005), Springer Science and Business Media LLC[DOI]
- Kirsteen J. Campbell, "Targeting BCL-2 regulated apoptosis in cancer", Open Biology, 8(5), pp.180002~ (2018), The Royal Society[DOI]
- Shoude Zhang, "Retraction Note: Jacarelhyperol A induced apoptosis in leukaemia cancer cell through inhibition the activity of Bcl-2 proteins", BMC Cancer, 22(1) (2022), Springer Science and Business Media LLC[DOI]
- Cheng, Y., "Autophagy and Tumor Cell Death", Adv Exp Med Biol, 1207, pp.339~349 (2020)
- Yan Cheng, "Autophagy and Tumor Cell Death", Autophagy: Biology and Diseases, pp.339~349 (2020), Springer Singapore[DOI]
- Marta Pérez-Hernández, "Targeting Autophagy for Cancer Treatment and Tumor Chemosensitization", Cancers, 11(10), pp.1599~ (2019), MDPI AG[DOI]
- Wu, Z. Z., "Expression of autophagy related genes mTOR, Becline-1, LC3 and p62 in the peripheral blood mononuclear cells of systemic lupus erythematosus", Am J Clin Exp Immunol, 6(1), pp.1~8 (2017)
- Zhang, M., "Expression of autophagy-related protein LC3B, p62, and cytoplasmic p53 in human retinoblastoma tissues", Eur Rev Med Pharmacol Sci, 20(15), pp.3152~3160 (2016)
- Baeva, M. E., "The role of autophagy protein Atg5 in multiple sclerosis", Mult Scler Relat Disord, 79, pp.105029~ (2023)